143 related articles for article (PubMed ID: 35392867)
1. DNA methylation molecular subtypes for prognosis prediction in lung adenocarcinoma.
Xu D; Li C; Zhang Y; Zhang J
BMC Pulm Med; 2022 Apr; 22(1):133. PubMed ID: 35392867
[TBL] [Abstract][Full Text] [Related]
2. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
3. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
[TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic values of the transcription factor-CpG-gene triplets in lung adenocarcinoma: A narrative review.
Lian D; Lian L; Zeng D; Zhang M; Chen M; Liu Y; Ying W; Zhou S
Medicine (Baltimore); 2022 Dec; 101(50):e32045. PubMed ID: 36550923
[TBL] [Abstract][Full Text] [Related]
6. Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma.
Wang P; Xu G; Gao E; Xu Y; Liang L; Jiang G; Duan L
Oxid Med Cell Longev; 2022; 2022():8802303. PubMed ID: 35814273
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of GSTM5 in lung adenocarcinoma is associated with DNA hypermethylation and poor prognosis.
Hao X; Zhang J; Chen G; Cao W; Chen H; Chen S
BMC Cancer; 2022 Jun; 22(1):685. PubMed ID: 35729618
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
Li XS; Nie KC; Zheng ZH; Zhou RS; Huang YS; Ye ZJ; He F; Tang Y
BMC Cancer; 2021 Jan; 21(1):96. PubMed ID: 33485313
[TBL] [Abstract][Full Text] [Related]
9. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
Wang H; Wei C; Pan P; Yuan F; Cheng J
Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Effects of Different Levels of Genomic Data for the Staging of Lung Adenocarcinoma: An Illustrative Study.
Li Y; Mansmann U; Du S; Hornung R
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946821
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtypes based on DNA promoter methylation predict prognosis in lung adenocarcinoma patients.
Shi S; Xu M; Xi Y
Aging (Albany NY); 2020 Nov; 12(23):23917-23930. PubMed ID: 33237038
[TBL] [Abstract][Full Text] [Related]
12. GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma.
Yu Y; Wang Z; Zheng Q; Li J
Gene; 2021 Jul; 790():145689. PubMed ID: 33964375
[TBL] [Abstract][Full Text] [Related]
13. Methylation- and homologous recombination deficiency-related mutant genes predict the prognosis of lung adenocarcinoma.
Nie GJ; Liu J; Zou AM; Zhan SF; Liang JK; Sui Y; Chen YN; Yao WS
J Clin Lab Anal; 2022 Apr; 36(4):e24277. PubMed ID: 35238419
[TBL] [Abstract][Full Text] [Related]
14. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
15. A novel subtype based on driver methylation-transcription in lung adenocarcinoma.
Wang X; Xu Z; Zhao S; Song J; Yu Y; Yang H; Hou Y
J Cancer Res Clin Oncol; 2024 May; 150(5):269. PubMed ID: 38777866
[TBL] [Abstract][Full Text] [Related]
16. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
17. Aberrant CpG-methylation affects genes expression predicting survival in lung adenocarcinoma.
He W; Ju D; Jie Z; Zhang A; Xing X; Yang Q
Cancer Med; 2018 Nov; 7(11):5716-5726. PubMed ID: 30353687
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.
Li H; Tong L; Tao H; Liu Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32031203
[TBL] [Abstract][Full Text] [Related]
19. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
20. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
